| Aug 5 |
Axsome (AXSM) Q2 Loss Widens Y/Y, Revenues Beat Estimates
|
| Aug 5 |
Axsome Therapeutics, Inc. (AXSM) Q2 2024 Earnings Call Transcript
|
| Aug 5 |
Earnings summary: Axsome Therapeutics Q2 net product revenue grows 87% Y/Y
|
| Aug 5 |
Axsome Therapeutics GAAP EPS of -$1.67 misses by $0.34, revenue of $87.2M beats by $0.27M
|
| Aug 5 |
Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
|
| Aug 2 |
Axsome Therapeutics Q2 2024 Earnings Preview
|
| Jul 30 |
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Shift From Loss To Profit
|
| Jul 30 |
Zacks Industry Outlook Highlights Moderna, Sarepta Therapeutics, Halozyme Therapeutics, Krystal Biotech and Axsome Therapeutics
|
| Jul 24 |
Jim Cramer Calls Axsome A 'Double Or Nothing Stock,' Says SAP Is 'Incredible'
|
| Jul 23 |
7 Biotech Stocks to Keep on Your Clinical Radar
|
